3 completed, 1 active not recruiting, 1 terminated, 1 unknown. 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 3, Active not recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
Follow Patient Preference: new trials by email Literature Review of Patient Preference trials Research Report on Patient Preference
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia Subcutaneous azacitidine, Oral decitabine/cedazuridine - Myelodysplastic Syndromes, Leukemia, Myeloid, Acute | Phase 3 | Active not recruiting | Otsuka Australia Pharmaceutical Pty Ltd | 13 | 2023-12-20 | 2025-03-20 |
| A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC), Pertuzumab IV, Trastuzumab IV - Early Breast Cancer, Locally Advanced Breast Cancer | Phase 3 | Completed | Hoffmann-La Roche | 346 | 2022-07-05 | 2026-02-10 |
| Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer Apalutamide, Enzalutamide - Prostate Cancer | Phase 3 | Terminated | Chinese University of Hong Kong | 74 | 2020-07-20 | 2026-10-27 |
| Nasal Fentanyl for Chronic Cancer Pain intranasal fentanyl spray, slow release morphine - Cancer, Pain | Phase 3 | Withdrawn | Norwegian University of Science and Technology | 2017-01-01 | 2020-12-10 | |
| Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer pazopanib, sunitinib - Carcinoma, Renal Cell | Phase 3 | Completed | Novartis Pharmaceuticals | 169 | 2010-05-17 | 2017-04-17 |
| Oxycodone/Naloxone (OXN) Combination in Moderate to Severe Non-malignant Pain Oxycodone and naloxone - Pain | Phase 3 | Completed | Mundipharma Pharmaceuticals B.V. | 174 | 2009-06-01 | 2013-02-12 |
| Flexible, Intensive vs. Conventional Insulin Therapy in Insulin-Naive Adults With Type 2 Diabetes conventional vs. flexible, intensive insulin therapy - Type 2 Diabetes | Phase 3 | Unknown | University of Jena | 38 | 2004-01-01 | 2007-02-27 |
Neoplasms (2) · Pain (2) · Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Diabetes Mellitus, Type 2 (1) · Hypoglycemia (1) · Inflammatory Breast Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Myelodysplastic Syndromes (1) · Patient Satisfaction (1) · Prostatic Neoplasms (1)
Behavior (7) · Health Behavior (7) · Treatment Adherence and Compliance (7) · Patient Satisfaction (6) · Neoplasms (3) · Neoplasms by Site (3) · Pathological Conditions, Signs and Symptoms (3) · Male Urogenital Diseases (2) · Neoplasms by Histologic Type (2) · Neurologic Manifestations (2) · Signs and Symptoms (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Adenocarcinoma (1) · Bone Marrow Diseases (1)
Ado-Trastuzumab Emtansine (1) · Injections, Subcutaneous (1) · Naloxone (1) · Oxycodone (1) · Radiotherapy (1) · Sunitinib (1) · Surgical Procedures, Operative (1) · Trastuzumab (1) · apalutamide (1) · decitabine and cedazuridine drug combination (1) · enzalutamide (1) · pazopanib (1) · pertuzumab (1)
Chinese University of Hong Kong (1) · Hoffmann-La Roche (1) · Mundipharma Pharmaceuticals B.V. (1) · Norwegian University of Science and Technology (1) · Novartis Pharmaceuticals (1) · Otsuka Australia Pharmaceutical Pty Ltd (1) · University of Jena (1)
Germany (2) · Argentina (1) · Australia (1) · Belgium (1) · Bosnia and Herzegovina (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Chile (1) · Costa Rica (1) · Croatia (1) · Finland (1) · France (1) · Hong Kong (1) · India (1)
Anoop Enjeti (1) · Chi Fai NG, MD (1) · Christof Kloos, MD (1) · Stein Kaasa, MD prof (1)
PMID 17717285, PMID 24687826, PMID 26457466, PMID 35011579, PMID 37146227
2008 (1), 2023 (1)